Medtronic announced that the first patients have enrolled in the pivotal trial of its its next-generation integrated insulin pump and continuous glucose monitoring system and the Predictive Low Glucose Management algorithm. Up to 84 patients will enroll in the trial at 8 centers across the U.S.
Quest Diagnostics, a medical testing services company that serves about half of all physicians and hospitals in the U.S., is investing $9.3 million into its new Tampa, FL national logistics hub.
In a regulatory win, Washington's Vesiflo got an FDA green light to market its replaceable urinary prosthesis for female adults with bladder drainage problems.
St. Jude Medical reported modest gains in third-quarter sales, supported by new products that include its CardioMEMS heart failure monitoring system.
Researchers have identified a hormone that is associated with fructose, fibroblast growth factor 21 (FGF21), which increases rapidly in the blood after fructose ingestion. High FGF21 levels in the blood are associated with obesity, insulin resistance and nonalcoholic fatty liver disease in both humans and animals.
Johnson & Johnson provided a first glimpse of what its devices and diagnostics business will look like after the divestiture of the Ortho Clinical Diagnostics business. The conglomerate gained about $1.1 billion from its sale, which closed on June 30. Excluding the operational impact, the Ortho-Clinical deal boosted sales growth figures for the device and diagnostics unit, as well as the company overall.
Amid recent efforts to rejuvenate its healthcare business, Philips is developing a diagnostic system with a Netherlands-based university medical center to improve outcomes for patients with chronic obstructive pulmonary disease.
The NIH is providing $10.8 million in grants over four years to 12 institutions toward developing computational tools to collect and analyze large-scale health data generated by mobile and wearable sensors.
Engineers have developed a tiny sensor used to measure the brain pressure in lab mice that they believe has the potential to create the electronic equivalent of touch for advanced prosthetics as well as other applications in medicine.
Sarasota, FL's RPS Diagnostics, maker of point-of-care diagnostic tests for eye conditions, announced Oct. 13 that it has closed a $28 million debt financing with healthcare-focused investment firm OrbiMed.
Invitae already provides testing for at least 15 genetic panels associated with particular diseases for $1,500 each with results coming on average in three weeks. Now it's raised $120 million Series F financing round to build-out its testing infrastructure and expand its global presence.
The FDA approved VisionCare Ophthalmic Technologies' Implantable Miniature Telescope in patients with bilateral end-stage age-related macular degeneration aged 65 or older, the company announced today.
Sterilization and infection prevention products and services company Steris will acquire its more globally-focused peer Synergy Health in a cash and stock deal worth about $1.9 billion.
C.R. Bard's Lutonix 035 Drug Coated Balloon Catheter became the first drug-coated balloon to receive PMA approval from the FDA on Oct. 10. It is indicated for the reopening of narrowed or blocked arteries in the knee or thigh in patients with peripheral artery disease.
Astute Medical will receive $30 million from funding partner CRG.
As med tech companies search for innovative ways to improve device implantation and patient outcomes, a new coating technology from Harvard University scientists could reduce blood clotting and bacterial infection associated with commonly used medical devices.
The U.S. Food and Drug Agency approved Bracco Diagnostics' Lumason, a contrast agent used for patients whose echocardiogram images are difficult to see with ultrasound imaging.
European Union antitrust regulators will now rule on the proposed $13.4 acquisition of Biomet by Zimmer by March 11, instead of Feb. 16, according to the European Commission's website.
Deerfield Management is looking to back a startup that's cornering about one-quarter of the world's supply of a radioisotope commonly used to create diagnostic imaging agents, molybdenum-99 (moly-99). The firm has backed Shine Medical Technologies, which has a novel technology to produce this material, with up to $125 million in debt and equity to build a manufacturing plant in Wisconsin.